Reactivation of hepatitis B virus infection in patients with hemo-lymphoproliferative diseases, and its prevention

Reactivation of hepatitis B virus (HBV) replication is characterized by increased HBV-DNA serum values of about 1 log or by HBV DNA turning positive if previously undetectable in serum, possibly associated with liver damage and seldom life-threatening. Due to HBV reactivation, hepatitis B surface an...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:World journal of gastroenterology : WJG Ročník 25; číslo 26; s. 3299
Hlavní autoři: Sagnelli, Caterina, Pisaturo, Mariantonietta, Calò, Federica, Martini, Salvatore, Sagnelli, Evangelista, Coppola, Nicola
Médium: Journal Article
Jazyk:angličtina
Vydáno: United States 14.07.2019
Témata:
Antibiotic Prophylaxis - methods
Antiviral Agents - therapeutic use
DNA, Viral - blood
Hepatitis B - immunology
Hepatitis B - prevention & control
Hepatitis B - virology
Hepatitis B Antibodies - blood
Hepatitis B Antibodies - immunology
Hepatitis B Surface Antigens - blood
Hepatitis B Surface Antigens - immunology
Hepatitis B virus - genetics
Hepatitis B virus - immunology
Hepatitis B virus - isolation & purification
Humans
Immunosuppressive Agents - adverse effects
Lymphoproliferative Disorders - drug therapy
Lymphoproliferative Disorders - immunology
Time Factors
Virus Activation - drug effects
Virus Activation - immunology
Hepatitis B virus reactivation
Hemo-lymphoproliferative diseases
Immunosuppressive therapy
Hepatitis B virus prophylasis
Hepatitis B virus therapy
Hepatitis B virus infection
ISSN:2219-2840, 2219-2840
On-line přístup:Zjistit podrobnosti o přístupu
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!
Popis
Shrnutí:Reactivation of hepatitis B virus (HBV) replication is characterized by increased HBV-DNA serum values of about 1 log or by HBV DNA turning positive if previously undetectable in serum, possibly associated with liver damage and seldom life-threatening. Due to HBV reactivation, hepatitis B surface antigen (HBsAg)-negative/anti-HBc-positive subjects may revert to HBsAg-positive. In patients with hemo-lymphoproliferative disease, the frequency of HBV reactivation depends on the type of lymphoproliferative disorder, the individual's HBV serological status and the potency and duration of immunosuppression. In particular, it occurs in 10%-50% of the HBsAg-positive and in 2%-25% of the HBsAg- negative/anti-HBc-positive, the highest incidences being registered in patients receiving rituximab-based therapy. HBV reactivation can be prevented by accurate screening of patients at risk and by a pharmacological prophylaxis with anti-HBV nucleo(t)sides starting 2-3 wk before the beginning of immunosuppressive treatment and covering the entire period of administration of immunosuppressive drugs and a long subsequent period, the duration of which depends substantially on the degree of immunodepression achieved. Patients with significant HBV replication before immunosuppressive therapy should receive anti-HBV nucleo(t)sides as a long-term (may be life-long) treatment. This review article is mainly directed to doctors engaged every day in the treatment of patients with onco-lymphoproliferative diseases, so that they can broaden their knowledge on HBV infection and on its reactivation induced by the drugs with high immunosuppressive potential that they use in the care of their patients.
Bibliografie:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
ObjectType-Review-3
content type line 23
ISSN:2219-2840
2219-2840
DOI:10.3748/wjg.v25.i26.3299